https://scholars.lib.ntu.edu.tw/handle/123456789/581786
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Kanda T. | en_US |
dc.contributor.author | Lau G.K.K. | en_US |
dc.contributor.author | Wei L. | en_US |
dc.contributor.author | Moriyama M. | en_US |
dc.contributor.author | Yu M.-L. | en_US |
dc.contributor.author | Chuang W.-L. | en_US |
dc.contributor.author | Ibrahim A. | en_US |
dc.contributor.author | Lesmana C.R.A. | en_US |
dc.contributor.author | Sollano J. | en_US |
dc.contributor.author | Kumar M. | en_US |
dc.contributor.author | Jindal A. | en_US |
dc.contributor.author | Sharma B.C. | en_US |
dc.contributor.author | Hamid S.S. | en_US |
dc.contributor.author | Kadir Dokmeci A. | en_US |
dc.contributor.author | Mamun-Al-Mahtab, McCaughan G.W. | en_US |
dc.contributor.author | Wasim J. | en_US |
dc.contributor.author | Crawford D.H.G. | en_US |
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.contributor.author | Ooka Y. | en_US |
dc.contributor.author | Yokosuka O. | en_US |
dc.contributor.author | Sarin S.K. | en_US |
dc.contributor.author | Omata M. | en_US |
dc.date.accessioned | 2021-09-04T05:16:47Z | - |
dc.date.available | 2021-09-04T05:16:47Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074431342&doi=10.1007%2fs12072-019-09988-7&partnerID=40&md5=b3f3be24b5840188c9bb5ddd34c2c402 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/581786 | - |
dc.description.abstract | In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection who achieved SVR in short term. HCC occurrence was more often observed in patients with previous HCC history. We found occurrence of HCC in 178 (29.6%) of 602 patients with previous HCC history (15.4?months mean follow-up post-DAA initiation) but, in contrast, in only 604 (1.3%) of 45,870 patients without previous HCC history (18.2?months mean follow-up). Thus, in these guidelines, we recommend the following: in patients with previous HCC history, surveillance at 4-month intervals for HCC by ultrasonography (US) and tumor markers should be performed. In patients without previous HCC history, surveillance at 6- to 12-month intervals for HCC including US is recommended until the long-term DAA treatment effects, especially for the resolution of liver fibrosis, are confirmed. This guideline also includes recommendations on how to follow-up patients who have been infected with both HCV and HBV. When HCV was eradicated in these HBsAg-positive patients or patients with previous HBV infection (anti-HBc and/or anti-HBs-positive), it was shown that HBV reactivation or HBV DNA reappearance was observed in 67 (41.4%) of 162 or 12 (0.9%) of 1317, respectively. For these co-infected patients, careful attention should be paid to HBV reactivation for 24?weeks post-treatment. ? 2019, The Author(s). | - |
dc.publisher | Springer | - |
dc.relation.ispartof | Hepatology International | - |
dc.subject | DAA; Follow-up; Guideline; HBV; HCC; HCV; SVR | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antivirus agent; asunaprevir plus daclatasvir; entecavir; ledipasvir plus sofosbuvir; ribavirin plus sofosbuvir; simeprevir plus sofosbuvir; tenofovir; unclassified drug; antivirus agent; adult; aged; Article; bilirubin blood level; controlled study; disease association; drug efficacy; echography; female; follow up; hepatitis B; hepatitis C; human; liver cell carcinoma; liver fibrosis; major clinical study; male; middle aged; mixed infection; nuclear magnetic resonance imaging; platelet count; practice guideline; priority journal; sustained virologic response; very elderly; viral clearance; virus reactivation; x-ray computed tomography; complication; Hepacivirus; hepatitis B; Hepatitis B virus; hepatitis C; liver cell carcinoma; liver tumor; mixed infection; practice guideline; virology; virus activation; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Sustained Virologic Response; Virus Activation | - |
dc.title | APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s12072-019-09988-7 | - |
dc.identifier.pmid | 31541423 | - |
dc.identifier.scopus | 2-s2.0-85074431342 | - |
dc.relation.pages | 649-661 | - |
dc.relation.journalvolume | 13 | - |
dc.relation.journalissue | 6 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。